{"entity":{"id":"andrew-wagner","kind":"person","name":"Andrew J. Wagner","aka":[],"tldr":"Boston sarcoma doctor who first showed that mTOR inhibitors shrink perivascular epithelioid cell tumours and then led AMPECT, the trial that made nab-sirolimus the first approved treatment for these rare cancers.","summary":"Andrew Wagner is a medical oncologist in the sarcoma centre at Dana-Farber Cancer Institute. He was first author of the 2010 Journal of Clinical Oncology report showing responses to sirolimus in malignant perivascular epithelioid cell tumours, linking their TSC1/TSC2 loss to mTOR dependence, and of the 2021 Journal of Clinical Oncology report of AMPECT, the phase 2 trial in which nab-sirolimus produced durable responses in advanced malignant PEComa, the basis of the first approval for the disease.","asOf":"2026-09-18","links":[],"tags":["sarcoma","rare-cancers","targeted-therapy","trialist"],"related":[],"cancers":["pecoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021","paper-wagner-sirolimus-pecoma-jco-2010"],"journals":[],"dependsOn":[],"notes":[],"role":"Sarcoma medical oncologist, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["PEComa","mTOR inhibitors","Rare sarcomas"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wagner%5BAuthor%5D"}],"papers":[]},"route":"/people/andrew-wagner/","neighbours":{"cancer":[{"id":"pecoma","kind":"cancer","name":"Perivascular epithelioid cell tumour (PEComa)","route":"/cancers/pecoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}],"paper":[{"id":"paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021","kind":"paper","name":"AMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours","route":"/key-papers/paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021/"},{"id":"paper-wagner-sirolimus-pecoma-jco-2010","kind":"paper","name":"Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumours","route":"/key-papers/paper-wagner-sirolimus-pecoma-jco-2010/"}]}}